This Falling Scalpel Could Cut You

In this video, health-care analysts David Williamson and Max Macaluso discuss the recent 20% plunge suffered by Edwards Lifesciences investors and whether the factors behind the substantial revenue miss make the stock a bad news buy or if investors will be cut trying to catch a falling knife.

We all would like to build long-term wealth and retire well, but buying stocks after a sudden plunge isn't a surefire strategy. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and St. Jude Medical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2052552, ~/Articles/ArticleHandler.aspx, 7/24/2014 11:42:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement